Ally Bridge Group is a global healthcare investment management firm specializing in high-impact life science innovation. Founded in 2013 by Frank Yu, the firm operates from offices in New York and Hong Kong. Since its inception, Ally Bridge Group has led or co-led over $6 billion in transactions across various healthcare subsectors.

The firm's mission is to generate superior -adjusted returns for investors while addressing unmet medical needs. This is achieved by combining deep scientific and clinical research with proven M&A and capital markets expertise. Ally Bridge Group employs two complementary investment strategies: private equity, established in 2013, and public equity, launched in 2018.

By leveraging its global presence and local talent, the firm seeks to identify and secure opportunities in high-impact life science innovation. (